Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. The Pan-American Collaborative Retina Study Group at 24 Months

Ophthalmology

Volumn 116, Issue 8, 2009, Pages

  Arevalo, J Fernando ^a   Sanchez, Juan G ^b   Wu, Lihteh ^c   Maia, Mauricio ^d   Alezzandrini, Arturo A ^e   Brito, Miguel ^f   Bonafonte, Sergio ^g   Lujan, Silvio ^h   Diaz Llopis, Manuel ⁱ   Restrepo, Natalia ^b   Rodríguez, Francisco J ^j   Udaondo Mirete, Patricia ⁱ  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

^b Clínica Oftalmológica de Antioquia Instituto Nacional de Investigación en Oftalmología CLOFAN INIO   (Colombia)

^c Instituto de Cirugia Ocular   (Costa Rica)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f Instituto Docente de Especialidades Oftalmológicas IDEO   (Venezuela)

^g Centro de Oftalmología Bonafonte Barcelona   (Spain)

^h Centro Of almológico Mácula D and T   (Peru)

ⁱ UNIVERSITY OF VALENCIA   (Spain)

^j UNIVERSIDAD DEL ROSARIO   (Colombia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARGENTINA; ARTICLE; BRAZIL; CATARACT; CEREBROVASCULAR ACCIDENT; COLOMBIA; COMPARATIVE STUDY; CONTROLLED STUDY; COSTA RICA; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; FUNCTIONAL ANATOMY; HEART INFARCTION; HUMAN; HYPERTENSION; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEXICO; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PERU; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; SIDE EFFECT; SPAIN; THICKNESS; UNITED STATES; VENEZUELA; VISUAL ACUITY;

EID: 68049148355     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.03.016     Document Type: Article

References (63)

1. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. Nguyen Q.D., Tatlipinar S., Shah S.M., et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142 (2006) 961-969
3. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 91 (1984) 1464-1474
4. Richter B., and Kohner E. Medical interventions for diabetic retinopathy. In: Wormald R., Smeeth L., and Henshaw K. (Eds). Evidence-Based Ophthalmology (2004), BMJ Books, London 331-340
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
6. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 94 (1987) 761-774
7. Ferris III F.L., and Patz A. Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 28 suppl (1984) 452-461
8. Bresnick G.H. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 90 (1983) 1301-1317
9. Lee C.M., and Olk R.J. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 98 (1991) 1594-1602
10. Sutter F.K., Simpson J.M., and Gillies M.C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111 (2004) 2044-2049
11. Massin P., Aurden F., Haouchine B., et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111 (2004) 218-225
12. Gillies M.C., Sutter F.K., Simpson J.M., et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113 (2006) 1533-1538
13. Jonas J.B., Kamppeter B.A., Harder B., et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 22 (2006) 200-207
14. Audren F., Erginay A., Haouchine B., et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 84 (2006) 624-630
15. Pendergast S.D., Hassan T.S., Williams G.A., et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 130 (2000) 178-186
16. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
17. Chun D.W., Heier J.S., Topping T.M., et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113 (2006) 1706-1712
18. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005
19. Starita C., Patel M., Katz B., and Adamis A.P. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol 39 (2007) 122-148
20. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
21. Antcliff R.J., and Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14 (1999) 223-232
22. Funatsu H., Yamashita H., Ikeda T., et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110 (2003) 1690-1696
23. Funatsu H., Yamashita H., Sakata K., et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112 (2005) 806-816
24. Adamis A.P., Miller J.W., Bernal M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118 (1994) 445-450
25. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
26. Malecaze F., Clamens S., Simorre-Pinatel V., et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112 (1994) 1476-1482
27. Tolentino M.J., McLeod D.S., Taomoto M., et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133 (2002) 373-385
28. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103 (1996) 1820-1828
29. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
30. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (2006) 275-278
31. Michels S., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005) 1035-1047
32. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
33. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
34. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
35. Spandau U.H., Ihloff A.K., and Jonas J.B. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. [letter]. Acta Ophthalmol Scand 84 (2006) 555-556
36. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
37. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
38. Ladewig M.S., Ziemssen F., Jaissle G., et al. Intravitreal bevacizumab for neovascular age-related macular degeneration. [in German]. Ophthalmologe 103 (2006) 463-470
39. Oshima Y., Sakaguchi H., Gomi F., and Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142 (2006) 155-158
40. Bakri S.J., Donaldson M.J., and Link T.P. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. [letter]. Eye 20 (2006) 1474-1475
41. Mason III J.O., Albert Jr. M.A., Mays A., and Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26 (2006) 839-841
42. Shah P.K., Narendran V., Tawansy K.A., et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive retinopathy of prematurity. Indian J Ophthalmol 55 (2007) 75-76
43. Arevalo J.F., Fromow-Guerra J., Quiroz-Mercado H., et al., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114 (2007) 743-750
44. Maturi R.K., Bleau L.A., and Wilson D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 270-274
45. Shahar J., Avery R.L., Heilweil G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (2006) 262-269
46. Manzano R.P., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261
47. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effects to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 113 (1995) 1144-1155
48. Chieh J.J., Roth D.B., Liu M., et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 25 (2005) 828-834
49. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
50. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
51. Strom C., Sander B., Klemp K., et al. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 46 (2005) 3855-3858
52. Campochiaro P.A., and C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 45 (2004) 922-931
53. Miyamoto K., and Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol 14 (1999) 233-239
54. Miyamoto K., Khosrof S., Bursell S., et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96 (1999) 10836-10841
55. Vermes I., Steinmetz E.T., Zeyen L.J., and van der Veen E.A. Rheological properties of white blood cells are changed in diabetic patients with microvascular complications. Diabetologia 30 (1987) 434-436
56. Schröder S., Palinski W., and Schmid-Schönbein G.W. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139 (1991) 81-100
57. McLeod D.S., Lefer D.J., Merges C., and Lutty G.A. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 147 (1995) 642-653
58. Antonetti D.A., Barber A.J., Khin S., et al., Penn State Retina Research Group. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 47 (1998) 1953-1959
59. Soheilian M., Ramezani A., Bijanzadeh B., et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27 (2007) 1187-1195
60. Kumar A., and Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 55 (2007) 451-455
61. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115 (2008) 1447-1459
62. Schachat A.P. A new look at an old treatment for diabetic macular edema. Ophthalmology 115 (2008) 1445-1446
63. Schachat A.P., Chambers W.A., Liesegang T.J., and Albert D.A. Safe and effective. Ophthalmology 110 (2003) 2073-2074